Results for: Schizophrenia

The selection of appropriate treatment options for schizophrenia patients requires careful consideration of various factors, including efficacy, tolerability, and safety. However, the lack of reliable biomarkers makes it challenging to precisely match the mechanism of action of the drug to the patient’s specific pathology. Despite this, clinicians often rely on trial and error to find the most effective medication for each individual. The development of novel agents targeting dopaminergic neurotransmission offers promising opportunities, but researchers emphasize the need for better patient stratification and long-term safety monitoring. Combining new drugs with traditional medications may enhance treatment outcomes, but further research is necessary to evaluate potential safety risks.

Alto Neuroscience’s (ANRO) ALTO-101, a novel PDE4 inhibitor, has shown promising results in Phase 1 studies for cognitive impairment associated with schizophrenia (CIAS). The transdermal patch formulation of ALTO-101 demonstrated improved tolerability and pharmacokinetics compared to oral administration. Alto plans a proof-of-concept study in CIAS patients in H1 2024, with top-line data expected in H2 2025.

Leah, a woman diagnosed with schizophrenia, experiences challenges in forming and maintaining friendships due to the stigmas surrounding her condition and the pressure to appear perfect. This episode of the ‘How To!’ podcast features a discussion with psychotherapist Dr. Aleksandra Rayska on managing expectations, celebrating achievements, and coping with self-doubt.